Company Encyclopedia
View More
name
Zymeworks
ZYME.US
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
1.884 T
ZYME.USMarket value -Rank by Market Cap -/-

Financial Score

17/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking96/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-18.46%E
    • Profit Margin-47.16%E
    • Gross Margin-28.84%E
  • Growth ScoreB
    • Revenue YoY116.21%A
    • Net Profit YoY44.20%B
    • Total Assets YoY-18.45%E
    • Net Assets YoY-12.78%E
  • Cash ScoreB
    • Cash Flow Margin-212.02%D
    • OCF YoY116.21%A
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreA
    • Gearing Ratio19.43%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jazz Pharma rose 19%, Zymeworks increased by 34%

    Wallstreetcn·
    US
    ZYME
    +32.13%
    US
    JAZZ
    +21.51%
    Wallstreetcn·
    US
    ZYME
    +32.13%
    US
    JAZZ
    +21.51%

    Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment

    Zymeworks and Jazz Pharmaceuticals shares surged after announcing positive Phase 3 trial results for their cancer treatment, zanidatamab-hrii. Zymeworks' stock rose 59% to $29.45, while Jazz Pharmaceuticals' stock increased 31% to $184.99. The treatment, used with chemotherapy for HER2-positive gastroesophageal adenocarcinoma, showed a consistent safety profile. The companies plan to submit a supplemental biologics license application in 2026. The treatment is already approved for second-line biliary tract cancer under the name Ziihera.

    MorningStar·
    US
    JAZZ
    +21.51%
    US
    ZYME
    +32.13%
    MorningStar·
    US
    JAZZ
    +21.51%
    US
    ZYME
    +32.13%

    Zymeworks shares are trading higher after the company and its partners reported statistically significant and clinically meaningful improvements across PFS, OS, ORR, and DoR in the HERIZON-GEA-01 study.

    benzinga_article·
    US
    ZYME
    +32.13%
    benzinga_article·
    US
    ZYME
    +32.13%

    Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® ( zanidatamab-hrii ) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

    VANCOUVER, British Columbia, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...

    GlobeNewswire·
    US
    ZYME
    +32.13%
    GlobeNewswire·
    US
    ZYME
    +32.13%

    BUZZ-Jazz Pharma jumps after cancer drug meets main goal in late-stage study

    Jazz Pharmaceuticals' shares rose 13.4% premarket after its cancer drug, Ziihera, met main goals in a late-stage study for stomach cancer treatment. The study showed significant improvements in survival rates. Jazz shares rights with Zymeworks, whose shares also increased by 43.52% premarket. Jazz plans to submit a marketing application to the FDA in H1 2026. Ziihera is already approved for biliary tract cancer treatment. As of last close, Jazz shares are up 14.6% and Zymeworks 26.5% YTD.

    Reuters·
    US
    ZYME
    +32.13%
    US
    JAZZ
    +21.51%
    Reuters·
    US
    ZYME
    +32.13%
    US
    JAZZ
    +21.51%